Actinium-225 Targeted Agents: Where Are We Now?
Firas Mourtada1, Katsumi Tomiyoshi2, Jennifer Sims-Mourtada3
1Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA.
Brachytherapy
|September 10, 2023
Summary
Actinium-225 (²²⁵Ac) alpha-particle therapy offers precise cancer treatment with fewer side effects. Advances in ²²⁵Ac production and dosimetry are crucial for its effective clinical use in brachytherapy.
Area of Science:
- Nuclear Medicine
- Radiation Oncology
- Medical Physics
Background:
- Alpha-particle targeted radionuclide therapy presents a promising approach for cancer management.
- High linear energy transfer (LET) alpha emitters offer advantages over beta and gamma emitters, including targeted tumor cell kill and reduced normal tissue damage.
Purpose of the Study:
- To review recent advancements in Actinium-225 (²²⁵Ac) targeted radionuclide therapy.
- To address challenges in ²²⁵Ac source production, dosimetry, and clinical application for brachytherapy.
Main Methods:
- Literature review of recent studies on ²²⁵Ac production and characterization.
- Analysis of dosimetry modeling techniques for ²²⁵Ac brachytherapy.
- Summary of current clinical trials and outcomes using ²²⁵Ac.
Main Results:
- Actinium-225 (²²⁵Ac) shows significant potential due to its physical and chemical properties for brachytherapy.
- Challenges remain in ²²⁵Ac source availability, standardized dosimetry, and radiopharmaceutical production.
- Empirical dosing of ²²⁵Ac may lead to variable outcomes and toxicity.
Conclusions:
- Continued research in ²²⁵Ac production and dosimetry is essential for optimizing targeted radionuclide therapy.
- Standardized protocols are needed for safe and effective clinical implementation of ²²⁵Ac brachytherapy.
- Future directions include improved modeling and clinical studies to refine treatment strategies.
